Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
Mycopathologia ; 185(5): 917-923, 2020 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-32860564

RESUMEN

BACKGROUND: Candida auris is an emerging multidrug-resistant yeast that causes outbreaks in healthcare settings around the world. In 2016, clinicians and public health officials identified patients with C. auris bloodstream infections (BSI) in Colombian healthcare facilities. To evaluate potential risk factors and outcomes for these infections, we investigated epidemiologic and clinical features of patients with C. auris and other Candida species BSI. METHODS: We performed a retrospective case-case investigation in four Colombian acute care hospitals, defining a case as Candida spp. isolated from blood culture during January 2015-September 2016. C. auris BSI cases were compared to other Candida species BSI cases. Odds ratio (OR), estimated using logistic regression, was used to assess the association between risk factors and outcomes. RESULTS: We analyzed 90 patients with BSI, including 40 with C. auris and 50 with other Candida species. All had been admitted to the intensive care unit (ICU). No significant demographic differences existed between the two groups. The following variables were independently associated with C. auris BSI: ≥ 15 days of pre-infection ICU stay (OR: 5.62, CI: 2.04-15.5), evidence of severe sepsis (OR: 3.70, CI 1.19-11.48), and diabetes mellitus (OR 5.69, CI 1.01-31.9). CONCLUSION: Patients with C. auris BSI had longer lengths of ICU stay than those with other candidemias, suggesting that infections are acquired during hospitalization. This is different from other Candida infections, which are usually thought to result from autoinfection with host flora.


Asunto(s)
Candida/aislamiento & purificación , Candidemia/epidemiología , Candidiasis/diagnóstico , Diagnóstico Diferencial , Adulto , Antifúngicos/uso terapéutico , Candidemia/diagnóstico , Candidemia/tratamiento farmacológico , Candidiasis/tratamiento farmacológico , Candidiasis/epidemiología , Colombia/epidemiología , Infección Hospitalaria/diagnóstico , Infección Hospitalaria/epidemiología , Complicaciones de la Diabetes/microbiología , Brotes de Enfermedades , Femenino , Humanos , Control de Infecciones , Unidades de Cuidados Intensivos , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Factores de Riesgo , Sepsis/complicaciones , Sepsis/microbiología , Resultado del Tratamiento , Adulto Joven
2.
Clin Infect Dis ; 68(1): 15-21, 2019 01 01.
Artículo en Inglés | MEDLINE | ID: mdl-29788045

RESUMEN

Background: Candida auris is a multidrug-resistant yeast associated with hospital outbreaks worldwide. During 2015-2016, multiple outbreaks were reported in Colombia. We aimed to understand the extent of contamination in healthcare settings and to characterize the molecular epidemiology of C. auris in Colombia. Methods: We sampled patients, patient contacts, healthcare workers, and the environment in 4 hospitals with recent C. auris outbreaks. Using standardized protocols, people were swabbed at different body sites. Patient and procedure rooms were sectioned into 4 zones and surfaces were swabbed. We performed whole-genome sequencing (WGS) and antifungal susceptibility testing (AFST) on all isolates. Results: Seven of the 17 (41%) people swabbed were found to be colonized. Candida auris was isolated from 37 of 322 (11%) environmental samples. These were collected from a variety of items in all 4 zones. WGS and AFST revealed that although isolates were similar throughout the country, isolates from the northern region were genetically distinct and more resistant to amphotericin B (AmB) than the isolates from central Colombia. Four novel nonsynonymous mutations were found to be significantly associated with AmB resistance. Conclusions: Our results show that extensive C. auris contamination can occur and highlight the importance of adherence to appropriate infection control practices and disinfection strategies. Observed genetic diversity supports healthcare transmission and a recent expansion of C. auris within Colombia with divergent AmB susceptibility.


Asunto(s)
Anfotericina B/farmacología , Antifúngicos/farmacología , Candida/clasificación , Candida/efectos de los fármacos , Candidiasis/epidemiología , Candidiasis/microbiología , Farmacorresistencia Fúngica , Candida/genética , Candida/aislamiento & purificación , Portador Sano/epidemiología , Portador Sano/microbiología , Colombia/epidemiología , Microbiología Ambiental , Humanos , Pruebas de Sensibilidad Microbiana , Epidemiología Molecular , Tipificación Molecular , Técnicas de Tipificación Micológica , Secuenciación Completa del Genoma
3.
Emerg Infect Dis ; 25(7)2019 07.
Artículo en Inglés | MEDLINE | ID: mdl-31211679

RESUMEN

Candida auris is an emerging multidrug-resistant fungus that causes hospital-associated outbreaks of invasive infections with high death rates. During 2015-2016, health authorities in Colombia detected an outbreak of C. auris. We conducted an investigation to characterize the epidemiology, transmission mechanisms, and reservoirs of this organism. We investigated 4 hospitals with confirmed cases of C. auris candidemia in 3 cities in Colombia. We abstracted medical records and collected swabs from contemporaneously hospitalized patients to assess for skin colonization. We identified 40 cases; median patient age was 23 years (IQR 4 months-56 years). Twelve (30%) patients were <1 year of age, and 24 (60%) were male. The 30-day mortality was 43%. Cases clustered in time and location; axilla and groin were the most commonly colonized sites. Temporal and spatial clustering of cases and skin colonization suggest person-to-person transmission of C. auris. These cases highlight the importance of adherence to infection control recommendations.


Asunto(s)
Candida , Candidiasis/epidemiología , Candidiasis/microbiología , Enfermedades Transmisibles Emergentes/epidemiología , Enfermedades Transmisibles Emergentes/microbiología , Infección Hospitalaria , Brotes de Enfermedades , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Antifúngicos/farmacología , Antifúngicos/uso terapéutico , Candida/efectos de los fármacos , Candidemia/epidemiología , Candidemia/microbiología , Candidiasis/tratamiento farmacológico , Candidiasis/historia , Niño , Preescolar , Colombia/epidemiología , Enfermedades Transmisibles Emergentes/historia , Farmacorresistencia Fúngica , Femenino , Historia del Siglo XXI , Humanos , Lactante , Masculino , Pruebas de Sensibilidad Microbiana , Persona de Mediana Edad , Mortalidad , Evaluación del Resultado de la Atención al Paciente , Vigilancia en Salud Pública , Estaciones del Año , Adulto Joven
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA